Company profile
Rhythm Pharmaceuticals, Inc.
NASDAQ: RYTM · Healthcare · Biotechnology
#295 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
60CFH 54DQ 65GM 62SS 72
v0.1 · 65/100 weight · provisional
↑ market scale, 3-yr revenue growth · ↓ growth stability, return on equity
Methodology →Revenue TTM
$217.2M
Rev growth YoY (TTM)
+58.7%
Net income (FY)
-$196.5M
Employees
414
as of 2026-08-06
Market cap
$7.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$189.8M$189.8M2025
Net income-$196.5M-$196.5M2025
Operating income-$192.0M-$192.0M2025
Total assets$480.2M$480.2M2025
Liabilities$210.2M$210.2M2025
Equity$139.1M$139.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product103%
License-3%
By geography
Non-US100%
The read
What is Rhythm Pharmaceuticals, Inc.’s revenue?
Rhythm Pharmaceuticals, Inc. booked $189.8M in FY2025 revenue, growing 46% year over year — faster than most Healthcare companies we track, at a -103.6% net margin.
Peers · Healthcare
Strata Critical Medical, Inc.60CLifeMD, Inc.73Bbiote Corp.63CMaravai LifeSciences Holdings, Inc.53DStoke Therapeutics, Inc.60CHeartflow, Inc. Common Stock44DNeighbors
Suffolk →Key facts
CEODavid Meeker
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: RYTM
Employees414
IPO date2017-10-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.